Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

Inclusion Criteria:Patient who were diagnosed with type 1 MNV or PCVPatients who were treated using aflibercept between January 2021 and December 2022Patients underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months.Exclusion Criteria:Less than 6 months of tolerating-fluid phasePatients without indocyanine green angiography (ICGA) resultPatients who received other treatment for neovascular age-related macular degeneration (AMD), except for aflibercept (eg. ranibizumab, bevacizumab, or PDT)History of intraocular or periocular steroid injectionHistory of vitreoretinal surgery or glaucoma surgeryHistory of intraocular inflammationUncontrolled glaucoma (IOP ≥ 25mmHg)